The Lipid Lowering and Onset of Renal Disease (LORD) Trial: a Randomized Double Blind Placebo Controlled Trial Assessing the Effect of Atorvastatin on the Progression of Kidney Disease

Robert G Fassett; Madeleine J Ball; Iain K Robertson; Dominic P Geraghty; Jeff S Coombes


BMC Nephrology 

In This Article


The objective of the LORD Trial is to assess whether atorvastatin 10mg can slow the progression of CKD. Measures of oxidative stress and inflammation will be used to assess whether these are concomitantly affected by this statin treatment. If statins slow the progression of CKD, then most CKD patients may benefit from this treatment. Previous studies have been conducted in this area but have been either smaller, open labeled or short duration. Other studies, such as the SHARP study,[26] seek to assess the same question however they include the cholesterol absorption inhibitor ezetimibe in the treatment group, which may confuse the nature of the potential effective agent. The measure of eGFR every three months during the three-year trial is another strength of this protocol. We predict atorvastatin will slow the progression of CKD.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.